Phase 2 Study to Evaluate Safety and Efficacy of Rm-493 in Obese Patients
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of RM-493 on mean percent body weight
loss, and other weight loss parameters as well as Pharmacokinetic (PK) profile, and
ambulatory blood pressure in obese patients. The study is designed to evaluate the efficacy
and tolerability of a single dose of RM-493. The study drug (RM-493 and placebo) will be
administered subcutaneously in a blinded fashion.